Ranibizumab safe long-term for neovascular age-related macular degeneration

NEW YORK (Reuters Health) - Ranibizumab injections may be safely used for at least three years in patients with neovascular age-related macular degeneration (nAMD), according to findings from the SECURE study.

Full Story →